avatrombopag + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Thrombocytopenia Associated With Chronic Liver Disease

Conditions

Thrombocytopenia Associated With Chronic Liver Disease

Trial Timeline

Jul 1, 2014 → Apr 1, 2015

NCT ID

NCT02227693

About avatrombopag + Placebo

avatrombopag + Placebo is a phase 2 stage product being developed by Eisai for Thrombocytopenia Associated With Chronic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02227693. Target conditions include Thrombocytopenia Associated With Chronic Liver Disease.

What happened to similar drugs?

2 of 20 similar drugs in Thrombocytopenia Associated With Chronic Liver Disease were approved

Approved (2) Terminated (2) Active (16)

✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved

✅romiplostimAmgenApproved

🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3

🔄Avatrombopag + Placebo + Standard of careEisaiPhase 3

🔄Romiplostim + PlaceboKyowa KirinPhase 3

🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02227693	Phase 2	Completed	Jul 1, 2014	Apr 1, 2015	Thrombocytopenia Associated With Chronic Liver Disease

Competing Products

20 competing products in Thrombocytopenia Associated With Chronic Liver Disease

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Placebo	Eli Lilly	Phase 1/2	39
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	17
Placebo + Lusutrombopag	Shionogi	Phase 2	27
Lusutrombopag	Shionogi	Phase 2	27
Avatrombopag + Avatrombopag + Placebo	Eisai	Phase 2	35
avatrombopag	Eisai	Phase 1	29
E5501 + Drug: E5501	Eisai	Phase 1	29
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)	Eisai	Phase 3	40
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + Ribavirin	Eisai	Phase 2	35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)	Eisai	Phase 3	40
Avatrombopag + Placebo + Standard of care	Eisai	Phase 3	40
Romiplostim	Kyowa Kirin	Phase 1/2	32
Romiplostim + Placebo	Kyowa Kirin	Phase 3	40
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	35
Romiplostim and danazol	Kyowa Kirin	Phase 2	31
ONO-7746	Ono Pharmaceutical	Phase 1	21
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	29
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	47
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 2	42
TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)	Jiangsu Hengrui Medicine	Phase 2	31